Found: 4
Select item for more details and to access through your institution.
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 129, doi. 10.1002/hon.3163_87
- By:
- Publication type:
- Article
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 568, doi. 10.1002/hon.3164_425
- By:
- Publication type:
- Article
Long-term outcomes of thalidomide in refractory Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 41, n. 5, p. 429, doi. 10.1111/apt.13057
- By:
- Publication type:
- Article
Paternal age and autism are associated in a family-based sample.
- Published in:
- 2007
- By:
- Publication type:
- Letter